Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry

Journal of Chromatography A

Volumn 1020, Issue 1, 2003, Pages 27-34

  Guetens, Gunther ^a,b   De Boeck, Gert ^a   Highley, Martin ^a   Dumez, Herlinde ^a   Van Oosterom, Allan T ^a   De Bruijn, Ernst A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Gleevec; Glivec; Imatinib; Measurement of sediment technology; STI 571

Indexed keywords

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROTEINS; TUMORS;

ANTICANCER AGENTS; QUANTIFICATION;

CELLS;

IMATINIB;

ACCURACY; ANALYTIC METHOD; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ERYTHROCYTE LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; OBSERVER VARIATION; PRECIPITATION; PRIORITY JOURNAL; ROOM TEMPERATURE; TANDEM MASS SPECTROMETRY; TEMPERATURE SENSITIVITY;

ANTINEOPLASTIC AGENTS; ERYTHROCYTES; HUMANS; PIPERAZINES; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 1642263132     PISSN: 00219673     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9673(03)00775-1     Document Type: Conference Paper

References (17)

1. van Oosterom A.T., Judson I., Verweij J., Stroobants S., di Paola E.D., Dimitrijevic S., Martens M., Webb A., Sciot R., Van Glabbeke M., Silberman S., Nielsen O.S. Lancet. 358:2001;1421.
2. Bakhtiar R., Khemani L., Hayes M., Bedman T., Tse F. J. Pharm. Biomed. Anal. 28:2002;1183.
3. Bakhtiar R., Lohne J., Ramos L., Khemani L., Hayes M., Tse F. J. Chromatogr. B. 768:2002;325.
4. Highley M.S., de Bruijn E.A. Pharm. Res. 13:1996;186.
5. Driessen O., Highley M.S., Harper P.G., Maes R.A., de Bruijn E.A. Clin. Biochem. 27:1994;195.
6. Highley M.S., Pattyn G., Lambrechts H., de Bruijn E.A., van Oosterom A.T., Harper P.G. Eur. J. Cancer. 31A:1995;969.
7. Highley M.S., Momerency G., Van Cauwenberghe K., van Oosterom A.T., Schrijvers D., de Bruijn E.A., Maes R.A., Harper P.G. Eur. J. Cancer. 31A:1995;942.
8. Momerency G., Van Cauwenberghe K., Highley M.S., Harper P.G., van Oosterom A.T., de Bruijn E.A. J. Pharm. Sci. 85:1996;262.
9. Highley M.S., Harper P.G., Slee P.H., de Bruijn E.A. Int. J. Cancer. 65:1996;711.
10. Highley M.S., Schrijvers D., van Oosterom A.T., Harper P.G., Momerency G., Van Cauwenberghe K., Maes R.A., de Bruijn E.A., Edelstein M.B. Ann. Oncol. 8:1997;1139.
11. Schrijvers D., Highley M.S., de Bruijn E.A., van Oosterom A.T., Vermorken J. Anti-Cancer Drugs. 10:1999;147.
12. Loos W.J., van Zomeren D.M., Gelderboom H., Verweij J., Nooter K., Stoter G., Sparreboom A. J. Chromatogr. B. 766:2002;99.
13. Kerbusch T., Herben V.M.M., Jeuken M.J.J., Ouwekerk J., Keizer H.J., Beijnen J.H. Biopharm. Drug Dispos. 22:2001;99.
14. Dumez H., Highley M.S., Guetens G., De Boeck G., Hanauske A., van Oosterom A.T., Maes R.A., de Bruijn E.A., Harper P.G. Semin. Oncol. 28:2001;24.
15. Dumez H., Guetens G., De Boeck G., Highley M.S., Tjaden U.R., Maes R.A., Hanauske A., van Oosterom A.T., de Bruijn E.A. J. Sep. Sci. 24:2001;123.
16. Wildiers H., Guetens G., De Boeck G., Landut W., Verbeken E., Highley M.S., de Bruijn E.A., van Oosterom A.T. Int. J. Cancer. 99:2002;514.
17. Guetens G., Van Cauwenberghe K., De Boeck G., Maes R.A., Tjaden U.R., Van Der Greef J., de Bruijn E.A. J. Chromatogr. B. 739:2000;139.